JP2024038267A5 - - Google Patents

Download PDF

Info

Publication number
JP2024038267A5
JP2024038267A5 JP2024000646A JP2024000646A JP2024038267A5 JP 2024038267 A5 JP2024038267 A5 JP 2024038267A5 JP 2024000646 A JP2024000646 A JP 2024000646A JP 2024000646 A JP2024000646 A JP 2024000646A JP 2024038267 A5 JP2024038267 A5 JP 2024038267A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
carboxamide
oxopiperazine
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024000646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024038267A (ja
Filing date
Publication date
Priority claimed from JP2023567928A external-priority patent/JP7522943B2/ja
Application filed filed Critical
Publication of JP2024038267A publication Critical patent/JP2024038267A/ja
Publication of JP2024038267A5 publication Critical patent/JP2024038267A5/ja
Priority to JP2025264265A priority Critical patent/JP2026048891A/ja
Pending legal-status Critical Current

Links

JP2024000646A 2021-05-07 2024-01-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類 Pending JP2024038267A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025264265A JP2026048891A (ja) 2021-05-07 2025-12-18 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185637P 2021-05-07 2021-05-07
US63/185,637 2021-05-07
US202163286691P 2021-12-07 2021-12-07
US63/286,691 2021-12-07
JP2023567928A JP7522943B2 (ja) 2021-05-07 2022-05-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023567928A Division JP7522943B2 (ja) 2021-05-07 2022-05-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025264265A Division JP2026048891A (ja) 2021-05-07 2025-12-18 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Publications (2)

Publication Number Publication Date
JP2024038267A JP2024038267A (ja) 2024-03-19
JP2024038267A5 true JP2024038267A5 (cg-RX-API-DMAC10.html) 2024-10-23

Family

ID=81927873

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023567928A Active JP7522943B2 (ja) 2021-05-07 2022-05-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類
JP2024000646A Pending JP2024038267A (ja) 2021-05-07 2024-01-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類
JP2025264265A Pending JP2026048891A (ja) 2021-05-07 2025-12-18 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023567928A Active JP7522943B2 (ja) 2021-05-07 2022-05-05 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025264265A Pending JP2026048891A (ja) 2021-05-07 2025-12-18 Nav1.8阻害薬としてのシクロアルキル 3-オキソピペラジンカルボキサミド類及びシクロヘテロアルキル 3-オキソピペラジンカルボキサミド類

Country Status (21)

Country Link
US (1) US20220380338A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334293A1 (cg-RX-API-DMAC10.html)
JP (3) JP7522943B2 (cg-RX-API-DMAC10.html)
KR (1) KR102987078B1 (cg-RX-API-DMAC10.html)
CN (1) CN117881664A (cg-RX-API-DMAC10.html)
AR (1) AR125786A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022270115B2 (cg-RX-API-DMAC10.html)
BR (1) BR112023023239A2 (cg-RX-API-DMAC10.html)
CA (1) CA3217565A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003295A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023015096A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230519A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000242A (cg-RX-API-DMAC10.html)
EC (1) ECSP23083881A (cg-RX-API-DMAC10.html)
GE (2) GEP20257795B (cg-RX-API-DMAC10.html)
IL (1) IL308215A (cg-RX-API-DMAC10.html)
JO (1) JOP20230284A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013146A (cg-RX-API-DMAC10.html)
PE (1) PE20250021A1 (cg-RX-API-DMAC10.html)
TW (1) TWI827037B (cg-RX-API-DMAC10.html)
WO (1) WO2022235859A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013147A (es) * 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
KR20250120351A (ko) 2022-12-06 2025-08-08 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 치환된 테트라하이드로푸란 조절제의 합성을 위한 방법
WO2025085564A1 (en) * 2023-10-16 2025-04-24 Kronos Bio, Inc. Lysine acetyltransferase inhibitors
CN117645533B (zh) * 2023-10-20 2024-10-11 泰州精英化成医药科技有限公司 一种4-(三氟甲基)环己酮的合成方法
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
KR20260116140A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
KR20260116141A (ko) 2023-10-23 2026-07-28 버텍스 파마슈티칼스 인코포레이티드 통증 치료용 화합물 및 이의 고체 형태의 제조방법
KR20260118418A (ko) 2023-10-23 2026-07-30 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
CN117567323A (zh) * 2023-10-30 2024-02-20 湖北泰盛化工有限公司 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法
AU2024393245A1 (en) 2023-12-07 2026-06-18 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202606663A (zh) 2024-06-28 2026-02-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
LU605402B1 (en) 2024-07-11 2026-07-14 Sea4Us Biotecnologia E Recursos Marinhos Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52122392A (en) * 1976-04-07 1977-10-14 Sangyo Kagaku Kenkyu Kyokai Novel antibacterials
CA2550257A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
MX2007002410A (es) * 2004-08-30 2007-05-07 Neuromed Pharmaceuticals Ltd Derivados de urea como bloqueadores de canal de calcio.
EP2212290B1 (en) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
MX2010003864A (es) 2007-10-11 2010-06-01 Vertex Pharma Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CA2771472A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8889863B2 (en) 2010-07-16 2014-11-18 Vanderbilt University Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
BR112015018284B1 (pt) 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
CN105026373B (zh) 2013-01-31 2018-03-30 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ナトリウムチャネルの調節剤としてのスルホンアミド
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
JP2017114764A (ja) 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2015184383A1 (en) 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
KR101844984B1 (ko) 2016-05-31 2018-04-03 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR102714561B1 (ko) 2017-05-16 2024-10-10 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11419874B2 (en) 2017-11-23 2022-08-23 Oslo University Hospital Hf Treatment of tachycardia
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
GEAP202315648A (en) 2018-11-02 2023-07-25 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
WO2021108023A1 (en) 2019-11-26 2021-06-03 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11802122B2 (en) * 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
CN115697327A (zh) * 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺

Similar Documents

Publication Publication Date Title
IL308215A (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
IL299180A (en) 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS
FI4094804T3 (fi) Aryyliamidijohdannainen, jolla on kasvaimia estävä vaikutus
JP2024519487A5 (cg-RX-API-DMAC10.html)
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2021515004A5 (cg-RX-API-DMAC10.html)
JP2012528178A5 (cg-RX-API-DMAC10.html)
JP5667684B2 (ja) 関節炎の治療方法
JP2023525035A5 (cg-RX-API-DMAC10.html)
JP2010532386A5 (cg-RX-API-DMAC10.html)
RU2015113746A (ru) Замещенные сульфонамиды
JP2019038820A5 (cg-RX-API-DMAC10.html)
JP2024504364A5 (cg-RX-API-DMAC10.html)
IL276998B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
RU2018106453A (ru) Соединения
JP2014523851A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2013536168A5 (cg-RX-API-DMAC10.html)
JP2011506469A5 (cg-RX-API-DMAC10.html)
IL264982B (en) Hetero(aryl)cyclopropylamine compounds as lsd1 inhibitors
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
RU2016107974A (ru) Производные бензимидазолилметилмочевины в качестве агонистов alx рецептора
RU2018140250A (ru) Пролекарство производного аминокислоты
JP2013510884A5 (cg-RX-API-DMAC10.html)
JP2013531070A5 (cg-RX-API-DMAC10.html)